Evidence of Efficacy and Safety of Deucrictibant for Prophylaxis and On-Demand Treatment of Hereditary Angioedema Attacks Published Back-to-Back in The Lancet Haematology [Yahoo! Finance]
KalVista Pharmaceuticals: Has Potential But With Caveats [Seeking Alpha]
Validation of Patient-Reported Outcomes in the On-Demand Treatment of Hereditary Angioedema Attacks Published in Clinical Reviews in Allergy & Immunology
Pharvaris (PHVS) is now covered by Royal Bank Of Canada. They set an "outperform" rating and a $52.00 price target on the stock.
Pharvaris (PHVS) had its "buy" rating reaffirmed by HC Wainwright. They now have a $60.00 price target on the stock.